Past Coverage of the Duke Scandal

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Cancer Letter’s Past Coverage of The Duke Scandal

Oct. 2, 2009

A Biostatistics Paper Alleges Potential Harm to Patients In Two Duke Clinical Studies

Oct. 9, 2009

Duke University Suspends Two Clinical Trials After Journal Paper Questions Assay Validity

Oct. 23, 2009

Duke Halts Third Trial; Coauthor Disputes Claim That Data Validation Was Blinded.

Moffitt Ends Pilot Study Based On Duke Test, Says Action Unrelated

Jan. 29, 2010

Duke Plans To Restart Three Trials Using Tumor Microarray Analysis

May 14, 2010

NCI Raises New Questions About Duke Genomics Research, Cuts Assay From Trial

The Cancer Letter Obtains “Confidential” Documents From Duke IRB Investigation

Report Doesn’t Quell Concerns About Duke Genomics Research, Biostatisticians Say

July 16, 2010

Prominent Duke Scientist Claimed Prizes He Didn’t Win, Including Rhodes Scholarship.

July 23, 2010

By Defending Potti, Duke Officials Become Target Of Charges Of Institutional Failure

Duke Officials Decline To Provide Details Of Probe. Biostatisticians Write To Varmus Asking NCI To Investigate

The Lancet Oncology Issues “Expression Of Concern” Over Paper

Duke Insiders Allege Intimidation By Administration

July 30, 2010

Varmus, Duke Ask IOM To Investigate Potti’s Scientific Work, Clinical Trials

Michigan Scientist David Beer Sought Retraction Of Potti’s NEJM Paper Over Misuse Of His Data

Potti Claimed Rhodes Credential in Bio Submitted for DOD Funding

Duke Vice Dean Cuffe Promises Complete, Independent Probe Of Work By Potti, Nevins.

Oct. 1, 2010

An Impromptu Group Proposes Standards For Publication Of Genomics Research

IOM To Form Committee To Investigate Duke Genomics Research

Oct. 22, 2010

IOM Review Of Duke Genomics Trials To Focus On Validation, Scientific Criteria

Oct. 29, 2010

Nevins Retracts Key Paper By Duke Group, Raising Question Of Harm To Patients

Retraction Based On Data Given To Duke Last November, But Apparently Disregarded

Nov. 5, 2010

Duke Retraction May Alter IOM Investigation; Review Panel Membership Announced

Nov. 19, 2010

JCO Retracts Key Duke Genomics Paper; Duke Shuts Down Three Phase II Trials;

Anil Potti Resigns From Duke University

Jan. 7, 2011

IOM Committee Will Probe Duke Scandal Together With Other “Omics” Case Studies

NCI Releases 550 Pages of Internal Documents Related to Duke Scandal

Jan. 14, 2011

Duke Deans Acknowledge Withholding Key Document From Outside Reviewers

Jan. 28, 2011

FDA Auditors Spend Two Weeks at Duke, Nevins Loses Position in Reorganization

Feb. 4, 2011

The Lancet Oncology retracts Potti paper, NEJM doesn’t

March 4, 2011

The Duke Scandal: NEJM retracts Potti paper

April 1, 2011

Nevins: Duke Administration Did a “Very Good Job” of Handling the Crisis

April 15, 2011

Guest Editorial: Anil Potti hires “online reputation managers” as journals retract his biomarker research

June 3, 2011

Anil Potti Joins Myrtle Beach Private Practice

July 22, 2011

A Year at NCI: Harold Varmus Reflects on Provocative Questions, the Duke Scandal, Financial Disaster and Grant Review

July 29, 2011

Part II of Q&A With NCI Director Harold Varmus

Sept. 9, 2011

Duke Researchers Retract Paper from Blood; Dozens of Retractions of Potti’s Work Expected

Clinical Trial Participants Sue Duke University, Potti, Nevins and Others for Causing Harm

Sept. 16, 2011

Another Potti Paper Retracted

Dec. 9, 2011

Anil Potti Reprimanded by North Carolina Licensure Board

Duke University Settles 11 Medical Malpractice Cases Related to Potti’s trials

Excerpts From Potti’s Application to Practice Medicine In South Carolina

Dec. 16, 2011

Anil Potti Explains: “Coming from India, I Did Not Know This Was Not The Real Rhodes Scholarship”

Jan. 27, 2012

FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials

News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements

Feb. 10, 2012

60 Minutes to air segment on the “Deception at Duke”

Feb. 17, 2012

Nevins Reverses Position, Claims Potti Manipulated Data For Basis of Clinical Trials

Feb. 24, 2012

South Carolina Clinic and Anil Potti Part Ways

March 23, 2012

IOM Omics Committee Offers Blueprint to Prevent Other Duke-Style Disasters

Feb. 8, 2013

NCI Unveils Checklist for Omics Studies

Oct. 18, 2013

NCI Sets Rules For Omics Studies

Exit Joseph Nevins: Duke’s Genomics Luminary Quietly Leaves

Jan. 9, 2015

Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab

Jan. 16, 2015

Duke Scientist: I Hope NCI Doesn’t Get Original Data

Jan. 23, 2015

Duke’s Legal Stance: We Did No Harm

Jan. 23, 2015

Misconduct Expert Dissects Duke Scandal


As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers.